Audit of combination and high-dose antipsychotic treatment in the community

Psychiatrist

Volumn 37, Issue 9, 2013, Pages 302-307

  Rajan, Lovely ^a   Clarke, Ian ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; COMMUNITY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL RECORD REVIEW; PATIENT INFORMATION; SCHIZOPHRENIA;

EID: 84883856333     PISSN: 17583209     EISSN: 17583217     Source Type: Journal    
DOI: 10.1192/pb.bp.112.039750     Document Type: Article

References (29)

1. Royal College of Psychiatrists. Consensus Statement on High-Dose Antipsychotic Medication (Council Report CR138). Royal College of Psychiatrists, 2006.
2. Harrington M, Lelliott C, Paton C, Okocha C, Duffett R, Sensky T. The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatr Bull 2002; 26: 414-8.
3. Keks NA, Alston K, Hope J, Krapivensky N, Culhane C, Tanaghow A, et al. Use of antipsychotics and adjunctive medications by inner urban community psychiatric service. Aust N Z J Psychiatry 1999; 33: 896-901.
4. Ito C, Kubota Y, Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 1999; 53 (suppl): S35-40.
5. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2005; 187: 243-7.
6. Taylor M, Shajahan P, Lawrie SM. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry 2008; 69: 240-5.
7. Tungaraza TE, Gupta S, Jones J, Poole R, Slegg G. Polypharmacy and high-dose antipsychotic regimes in the community. Psychiatrist 2010; 34: 44-6.
8. Grech P, Taylor D. Long-term antipsychotic polypharmacy: how does it start, why does it continue? Therapeutic Advances in Psychopharmacology 2012; 2: 5-11.
9. Taylor D. Antipsychotic polypharmacy - confusion reigns. Psychiatrist 2010; 34: 41-3.
10. Fleischhacker WW, Heikkinen T, Olie JP, Landsberg W, Dwaele P, McQuade RD, et al. Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study. Eur Psychiatry 2008; 2 (suppl 23): s114-5.
11. Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo controlled trail. Am J Psychiatry 2007; 164: 1404-10.
12. Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomised, double-blind, placebo-controlled trial. Am J Psychiatry 2005; 162: 130-6.
13. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997; 171: 569-73.
14. Langan J, Shajahan P. Antipsychotic polypharmacy: review of mechanisms, mortality and management. Psychiatrist 2010; 34: 58-62.
15. National Collaborating Centre for Mental Health. Schizophrenia: The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Updated Edition). British Psychological Society and Royal College of Psychiatrists, 2010.
16. Royal Pharmaceutical Society of Great Britain, British Medical Association. British National Formulary 56. BMJ Books & Pharmaceuticals Press, 2008.
17. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines (10th edn). Informa Healthcare, 2009.
18. NHS Greater Glasgow and Clyde Health Board. High Dose Antipsychotic Therapy Guideline. NHS Greater Glasgow and Clyde, 2008.
19. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
20. Yorston G, Pinney A. Use of high dose antipsychotic medication. Psychiatr Bull 1997; 21: 566-9.
21. Hayhurst K. Pennine Care NHS Trust Antipsychotic Prescribing Audit. The University of Manchester, 2006 (http://www.south.manchester.ac.uk/psychiatry/ capri/documents/PennineCareAntipsychoticPrescribing Audit2005.pdf).
22. NHS Quality Improvement Scotland. Standards for Integrated Care Pathways for Mental Health. NHS Quality Improvement Scotland, 2007.
23. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012; 201: 481-5.
24. Paton C, Barnes TRE, Cavanagh M-R, Taylor D, Lelliott P. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n prescribing. Br J Psychiatry 2008; 192: 435-9.
25. Tyson PJ, Mortimer AM, Wheeler JA. High-dose antipsychotic treatment in clinical practice. A review, audit and survey of consultant psychiatrist opinions. Psychiatr Bull 1999; 23: 661-4.
26. Geddes JR, Freemantle N, Harrison P, Bebbington PE. Atypical antipsychotics in the treatment of schizophrenia - systematic review and meta-regression analysis. BMJ 2000; 321: 1371-6.
27. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173: 325-9.
28. Curkendall SM, Mo J, Glasser DB, Rose Stang M, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchwan, Canada. J Clin Psychiatry 2004; 65: 715-20.
29. Barnes TRE, Paton C. Role of the Prescribing Observatory for Mental Heath. Br J Psychiatry 2012; 201: 428-9.